Journal article
Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia
K Macartney, HF Gidding, L Trinh, H Wang, A Dey, B Hull, K Orr, J McRae, P Richmond, M Gold, N Crawford, JA Kynaston, P McIntyre, N Wood
JAMA Pediatrics | AMER MEDICAL ASSOC | Published : 2017
Abstract
IMPORTANCE: Incorporating combination vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunization schedules should be evaluated from a benefit-risk perspective. Use of MMRV vaccine poses challenges due to a recognized increased risk of febrile seizures (FSs) when used as the first dose in the second year of life. Conversely, completion by age 2 years of measles, mumps, rubella, and varicella immunization may offer improved disease control. OBJECTIVE: To evaluate the effect on safety and coverage of earlier (age 18 months) scheduling of MMRV vaccine as the second dose of measles-containing vaccine (MCV) in Australia. DESIGN, SETTING, AND PARTICIPANTS: Prospective a..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Drs Gidding and Wood are supported by Australian National Health and Medical Research Council Career Development Fellowships. Funding from the Australian Government Department of Health and the NHMRC Project Grant ID number 1049557 supported the conduct of the study.